Company: CERO
Filing Date: 2025-07-21
Form Type: S-1
Source: 0001213900-25-066152
Chunk: 138

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-21
Form: S-1
Chunk 138
---
, we have issued and sold 112,274 shares of Common Stock for aggregate proceeds of $7,509,103 under the Keystone Equity Financing. Sales of our Common Stock to Keystone under the Keystone Purchase Agreements, and the timing of any sales, will be determined by us from time to time in our sole discretion and will depend on a variety of factors, including, among other things, market conditions, the trading price of our Common Stock and determinations by us regarding the use of proceeds from any sale of such Common Stock. The net proceeds from any sales under the Keystone Equity Financing will depend on the frequency with, and prices at, which the Common Stock are sold to the Selling Securityholder. To the extent we sell shares under the Keystone Purchase Agreements, we currently plan to use any proceeds therefrom for working capital and other general corporate purposes. Pending other uses, we intend to invest the net proceeds to us in investment-grade, interest-bearing securities such as money market funds, certificates of deposit, or direct or guaranteed obligations of the U.S. government, or hold as cash. We cannot predict whether the net proceeds invested will yield a favorable return. Keystone is not obligated to buy any Common Stock under the Keystone Purchase Agreements if such shares, when aggregated with all other Common Stock then beneficially owned by Keystone and its respective affiliates (as calculated pursuant to Section 13(d) of the Exchange Act and Rule 13d-3 promulgated thereunder), would result in Keystone beneficially owning Common Stock in excess of 4.99% of the then-outstanding shares of Common Stock (the “Beneficial Ownership Limitation”). Concurrent with the execution of the Keystone Purchase Agreements, we entered into the Keystone Registration Rights Agreements, pursuant to which we agreed to provide Keystone with customary registration rights related to the shares issued under the Keystone Purchase Agreements. The Keystone Purchase Agreements and Keystone Registration Rights Agreements contain customary registration rights, representations, warranties, conditions and indemnification obligations by each party. The representations, warranties and covenants contained in such agreements were made only for purposes of such agreements and as of specific dates, were solely for the benefit of the parties to such agreements and are subject to certain important limitations. Keystone Purchase Agreements and Registration Statements In February 2024, we entered into the February 2024 Keystone Purchase Agreement with Keystone, pursuant to which we may sell and issue, and Keystone is obligated to purchase, up to $25,000,000 of shares of Common Stock; provided that the number of